Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

  • Mathilde Lefort (Ophavsperson)
  • Sifat Sharmin (Ophavsperson)
  • Johanna B. Andersen (Ophavsperson)
  • Sandra Vukusic (Ophavsperson)
  • Romain Casey (Ophavsperson)
  • Marc Debouverie (Ophavsperson)
  • Gilles Edan (Ophavsperson)
  • Jonathan Ciron (Ophavsperson)
  • Aurélie Ruet (Ophavsperson)
  • Jérôme De Sèze (Ophavsperson)
  • Elisabeth Maillart (Ophavsperson)
  • Hélène Zephir (Ophavsperson)
  • Pierre Labauge (Ophavsperson)
  • Gilles Defer (Ophavsperson)
  • Christine Lebrun-Frénay (Ophavsperson)
  • Thibault Moreau (Ophavsperson)
  • Eric Berger (Ophavsperson)
  • Pierre Clavelou (Ophavsperson)
  • Jean Pelletier (Ophavsperson)
  • Bruno Stankoff (Ophavsperson)
  • Olivier Gout (Ophavsperson)
  • Eric Thouvenot (Ophavsperson)
  • Olivier Heinzlef (Ophavsperson)
  • Abdullatif Al-Khedr (Ophavsperson)
  • Bertrand Bourre (Ophavsperson)
  • Olivier Casez (Ophavsperson)
  • Philippe Cabre (Ophavsperson)
  • Alexis Montcuquet (Ophavsperson)
  • Abir Wahab (Ophavsperson)
  • Jean Philippe Camdessanché (Ophavsperson)
  • Aude Maurousset (Ophavsperson)
  • Nasr H. Ben Nasr (Ophavsperson)
  • Karolina Hankiewicz (Ophavsperson)
  • Corinne Pottier (Ophavsperson)
  • Nicolas Maubeuge (Ophavsperson)
  • D Dimitri-Boulos (Ophavsperson)
  • Chantal Nifle (Ophavsperson)
  • David A. Laplaud (Ophavsperson)
  • Dana Horakova (Ophavsperson)
  • Eva K. Havrdova (Ophavsperson)
  • Raed Alroughani (Ophavsperson)
  • Guillermo Izquierdo (Ophavsperson)
  • Sara Eichau (Ophavsperson)
  • Serkan Ozakbas (Ophavsperson)
  • Francesco Patti (Ophavsperson)
  • Marco Onofrj (Ophavsperson)
  • Alessandra Lugaresi (Ophavsperson)
  • Murat Terzi (Ophavsperson)
  • Pierre Grammond (Ophavsperson)
  • Francois Grand’Maison (Ophavsperson)
  • Bassem Yamout (Ophavsperson)
  • A. Prat (Ophavsperson)
  • Marc Girard (Ophavsperson)
  • Pierre Duquette (Ophavsperson)
  • Cavit Boz (Ophavsperson)
  • M. Trojano (Ophavsperson)
  • Pamela McCombe (Ophavsperson)
  • Mark Slee (Ophavsperson)
  • Jeannette Lechner-Scott (Ophavsperson)
  • Recai Turkoglu (Ophavsperson)
  • Patrizia Sola (Ophavsperson)
  • D. Ferraro (Ophavsperson)
  • Franco Granella (Ophavsperson)
  • V. Shaygannejad (Ophavsperson)
  • Julie Prevost (Ophavsperson)
  • Davide Maimone (Ophavsperson)
  • Olga Skibina (Ophavsperson)
  • Katherine Buzzard (Ophavsperson)
  • Anneke Van der Walt (Ophavsperson)
  • Rana Karabudak (Ophavsperson)
  • Bart Van Wijmeersch (Ophavsperson)
  • Tunde Csepany (Ophavsperson)
  • Daniele Spitaleri (Ophavsperson)
  • Steve Vucic (Ophavsperson)
  • N. Koch-Henriksen (Aarhus University) (Ophavsperson)
  • F Sellebjerg (Ophavsperson)
  • Per Soelberg Soerensen (Ophavsperson)
  • Christensen C.C. Hilt Christensen (Ophavsperson)
  • Peter Vestergaard Rasmussen (Ophavsperson)
  • M-B Jensen (Ophavsperson)
  • J L Frederiksen (Ophavsperson)
  • S. Bramow (Ophavsperson)
  • Henrik K. Mathiesen (Ophavsperson)
  • Karen I. Schreiber (Ophavsperson)
  • H. Butzkueven (Ophavsperson)
  • Melinda Magyari (Ophavsperson)
  • Tomas Kalincik (Ophavsperson)
  • Emmanuelle Leray (Ophavsperson)

Datasæt

Beskrivelse

Abstract Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Methods Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Results Overall, 5,148 relapsing–remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. Conclusions This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled.
Dato for tilgængelighed2022
ForlagFigshare
  • Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

    Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., & 68 flereGout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand'Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T. & Leray, E., dec. 2022, I: BMC Medical Research Methodology. 22, 1, 155.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    Åben adgang
    Fil
    2 Citationer (Scopus)
    47 Downloads (Pure)

Citationsformater